Moltzahn, F; Thalmann, G N (2012). [Bone metastasis in prostate cancer]. Urologe, 51(1), pp. 20-6. Berlin: Springer-Verlag 10.1007/s00120-011-2741-1
|
Text
120_2011_Article_2741.pdf - Published Version Available under License Publisher holds Copyright. Download (400kB) | Preview |
Bone metastasis and skeletal complications have a devastating impact on the quality of life and are a major cause of morbidity in prostate cancer patients. In addition to established bone-targeted therapies, new drugs such as endothelin A receptor antagonists, MET and VEGFR-2 antagonists or radiopharmaceuticals are in the focus of development. The standard care in prostate cancer patients with bone metastases to prevent skeletal-related events (SRE) are bisphosphonates. Denosumab, a human monoclonal antibody against RANKL, appeared to be superior to zoledronic acid for prevention of SRE and has been shown to prolong bone metastases-free survival. In contrast to zoledronic acid, denosumab clearance is not dependent on kidney function and can be administered subcutaneously. Similar rates of toxicity were observed for both substances; however, long-term data for denosumab are limited.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Urology |
UniBE Contributor: |
Moltzahn, Felix Roman, Thalmann, George |
ISSN: |
0340-2592 |
Publisher: |
Springer-Verlag |
Language: |
German |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 14:38 |
Last Modified: |
05 Dec 2022 14:12 |
Publisher DOI: |
10.1007/s00120-011-2741-1 |
PubMed ID: |
22258372 |
Web of Science ID: |
000300320700004 |
BORIS DOI: |
10.7892/boris.15439 |
URI: |
https://boris.unibe.ch/id/eprint/15439 (FactScience: 222784) |
Actions (login required)
 |
Edit item |